TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Increase in infarction wall movement velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IGA mod 2011 0/1 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MTBS (Microtensile Bond Strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of premature and adhesive failures
Endpoint domain: Adverse events/effects
Primary endpoint: Social Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: General Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: implant motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to regain continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in infant weight from birth to 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of lactogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exclusive breastfeeding at 3 and 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean effective doses to the operator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ablation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-segment late loss at 9-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choice of advertised foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mask comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: apnea/hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: hours of utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: subjective sensation of rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gain of induced per-rotation nystagmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time constant of post-rotation nystagmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admissions
Endpoint domain: Mortality/survival
Primary endpoint: Respiratory Distress Assessment Instrument score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total cure or marked improvement in toenail condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Oral transit time (OTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pharyngeal transit time (PTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Requirement for strong opiates
Endpoint domain: Adverse events/effects
Primary endpoint: Requirement for rescue opiates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone mineral density (BMD) reduction at total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HAMD-17 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 6-min walk test distance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: adequate bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung function at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: quality of life scores at 3 and 12 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Use of medication for eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity of canine scent detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of canine scent detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Switching to low-fat milk
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Low-fat milk sales percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of instrument deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Apgar scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Days on the ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inhibition of platelet aggregation at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum inhibition of platelet aggregation within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average inhibition of platelet aggregation maximum from 2 to 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self-reported STI testing at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported STI diagnosis at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: criterion for recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Mean ALT levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of ALT levels (≤35 IU/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in FibroTest® serum fibrosis marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical effect
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: work effect
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: pain effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tumor imaging effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until return to baseline JBRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of symptom control after BoNT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic motor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reproductive health knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight gain over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incontinence‐associated dermatitis severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician satisfaction with bowel management system
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Economic savings from internal fecal devices
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: bacterial wound cultures
Endpoint domain: Adverse events/effects
Primary endpoint: amount of removed dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostatic effect of acute bleeding events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rate at 30 minutes after infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUC(0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of wasting (MUAC <22 cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: decline in MUAC during the second trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Difference in axial length measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in ACD measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Altered expression of inflammation- and carcinogenesis-related proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean T½ values of (99m) Tc‐DTPA aerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1/FVC value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cap value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ETVAC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricular geometry improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of postoperative right ventricular failure
Endpoint domain: Adverse events/effects
Primary endpoint: progression
Endpoint domain: Mortality/survival
Primary endpoint: 48-hour postoperative oxycodone equivalent consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain scores at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO risk level reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical site infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of incomplete evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fecal impaction
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum hyperemic flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Estimated 5-year EFS rate
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of risk factors for HIV, HBV, and HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in the number of HIV tests performed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: poorer cognitive performance overall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: greater cognitive decline overall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: greater decline in memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: duration of phototherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful block according to Vester‐Andersen's criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Matrix reasoning change score
Endpoint domain: Cognitive functioning
Primary endpoint: Stroop test change
Endpoint domain: Cognitive functioning
Primary endpoint: DSST change score
Endpoint domain: Cognitive functioning
Primary endpoint: Increased sleep state
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Arterial stiffness measured using carotid‐femoral pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean tissue concentration of cefazolin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pathological complete remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological negative rate of regional lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of EPCA-2.19 assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of EPCA-2.19 assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of EPCA-2.19 assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of loratadine
Endpoint domain: Adverse events/effects
Primary endpoint: Sniffin' Sticks TDI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: median CD4 cell count increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: carbohydrate cravings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hunger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total costs per woman screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain subscale of WOMAC index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function subscale of WOMAC index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of PPS (Post-Pericardiotomy Syndrome)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 2-month survival difference
Endpoint domain: Mortality/survival
Primary endpoint: time to culture negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to PCR negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peritoneal-relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean pCO(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean PEF variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SVRI at five hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DFS increment in permanent first molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Time to viral load testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of at least one unexplained medication discrepancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of the primary VO2 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline blood lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ALT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of pelvic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Inspiratory Capacity (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of catheter-associated infection
Endpoint domain: Adverse events/effects
Primary endpoint: risk of catheter-associated bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Goblet cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine quiescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: number of nocturnal voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort during screening mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin temperature under dressings and casts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Taste perception disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision-related quality of life (VRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inadequate glycemic control during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean daily glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean changes in Beck Depression Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrence rate of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Walking energy cost per unit of distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progress in clinical picture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Aneurysm exclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from sac growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Straining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Softening stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: work performed during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distance covered during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of ≥ Grade 3 late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: thrombosis rate in grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HDL-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Long-term all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of HD sessions with IME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type 1 diabetes development frequencies
Endpoint domain: Mortality/survival
Primary endpoint: First phase insulin release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number of urge incontinence episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awakening time after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior chamber cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-operative gastrointestinal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PVOsD1 at least 50% in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Y-BOCS total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Y-BOCS Obsession subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of partial and complete response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MASI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erectile function domain scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LUTS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental outcomes at six years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of stage 1 AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes